Calidi Biotherapeutics, Inc. CLDI
Set alert
At close · Oct 30
After hours · Oct 30, 6:15 PM ET
- YTD
- -96.32%
- 1 year
- -97.28%
- Open
- 0.667
- Prev close
- 0.6717
- Mkt cap
- 2.53M
- Vol
- 48.42K
- Avg vol
- 141.28K
- EPS
- -36.47
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.65
- High
- 0.688
- Forward P/E
- -1.57
- Beta
- 0.57
- Short ratio
- 0.88
- Inst. own
- 2.71%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.67
- 200-d avg
- 2.22
- 1y target
- 6.25
Key statistics
- Market cap
- 26.57M
- Enterprise value
- 24.96M
- Trailing P/E
- 0.00
- Forward P/E
- -1.57
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.04
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -47.57M
- Total cash
- 836.00K
- Total debt
- 8.73M
- Return on equity
- 0.00%
- Shares outstanding
- 18.85M
- Short % of float
- 5.77%
- 50-day average
- 1.67
- 200-day average
- 2.22
Analyst view
Consensus: none
- Target (low)
- 2.50
- Target (mean)
- 6.25
- Target (high)
- 10.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 27, 2024 | Ladenburg Thalmann | init | — | Buy |
| May 15, 2024 | Baird | main | Outperform | Outperform |
| Mar 21, 2024 | Baird | main | Outperform | Outperform |
| Mar 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 22, 2023 | HC Wainwright & Co. | init | — | Buy |
| Oct 9, 2023 | Baird | init | — | Outperform |
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- calidibio.com
News
- Calidi Biotherapeutics Reports Two Posters At European Society For Medical Oncology From Its RedTail Platform
- Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
- Calidi Biotherapeutics To Present Preclinical Data On CLD-401 And In Situ T-Cell Engager Programs At ESMO 2026, Highlighting Tumor Eradication And Antitumor Activity Findings
- Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Calidi Biotherapeutics Receives NYSE American Non-Compliance Notice
- Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
- Calidi Biotherapeutics Announces Registered Direct Offering 1,025,640 Shares At $1.17 Per Share
- Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
- Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Your note
Sign in to keep a note on CLDI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAMAISA ALLAN | Chief Executive Officer | Sale | Dec 16, 2024 | 66,712 |
| FIRST LIGHT ACQUISITION GROUP LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 11, 2023 | 0 |
| LEFTWICH SCOTT | Director | Stock Award(Grant) | Jun 27, 2024 | 560,873 |
| SCHOENECK JAMES A | Director | Stock Award(Grant) | Jun 27, 2024 | 1,071,780 |
| STEWART ALAN R | Director | Stock Award(Grant) | Jun 27, 2024 | 154,087 |
| VECCHIOLLA THOMAS A | Director | Stock Award(Grant) | Dec 20, 2023 | 365,105 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cable Car Capital LLC | 0.40% | 82,937 | 116.94K | Sep 29, 2024 |
| CPR Investments Inc. | 0.27% | 56,000 | 78.96K | Sep 29, 2024 |
| Red Wave Investments, LLC | 0.23% | 46,461 | 65.51K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.19% | 39,612 | 55.85K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.11% | 23,544 | 33.20K | Sep 29, 2024 |
| Delta Investment Management, LLC | 0.10% | 21,023 | 29.64K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.15% | 31,166 | 43.94K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.05% | 10,000 | 14.10K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.05% | 10,167 | 14.34K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 7,445 | 10.50K | Oct 30, 2024 |
| Brinker Capital Destinations Tr-Destinations Multi Strategy Alt Fd | 0.03% | 7,034 | 9.92K | Aug 30, 2024 |
| Driehaus Event Driven Fund | 0.01% | 2,436 | 3.43K | Sep 29, 2024 |